Proteomic Analysis of Low-Grade Serous Ovarian Cancer and Comparing It with Non-cancerous Ovarian
- 18 Downloads
In Iran, ovarian cancer is the eighth most common cancer. Serous is considered as the most common of all ovarian cancers. It is usually deadly due to late diagnosis. Moreover, as all studies so far have considered metastatic or high-stage ovarian cancer, this study sought low-grade ovarian serous in human, which is of high importance and aimed at obtaining protein biomarkers that may be useful in diagnosis and treatment of ovarian serous cancer.
Materials and Methods
In this experimental study, ten patients with proved low-grade serous ovarian cancer and ten women without ovarian cancer, healthy, and cancerous tissue samples were obtained to perform proteomics. All tissue proteins were purified using standard separation methods, and proteins were separated using two-dimensional electrophoresis. Healthy and tumorous tissue proteomes were compared, and the extent of protein expression was analyzed.
This study identified 212 proteins, 41 of which had changes in protein expression in cancer state. The expression of eight proteins was suppressed, and five proteins were expressed in cancerous group. Thirteen proteins in cancer sample showed increase in expression and 15 proteins reduced expression in cancerous tissue.
It seems that in this disease, the expression of a large number of proteins in cancerous tissues changed, most of them decreased or not expressed at all. These changed proteins can be effective as biomarker in diagnosis and treatment of this disease.
KeywordsProteomics Low-grade serous ovarian cancer Comparison Non-cancerous ovarian
All authors had equal role in design, work, statistical analysis, and manuscript writing.
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
Human and Animal Rights
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Also ethics committee of Shahid Beheshti University of Medical Sciences approved this study by IR.SBMU.RETECH.REC.1396.709.
Informed consent was obtained from all individual participants included in the study.
- 2.Nouri D, Roshvand Z. Molecular genetics gene therapy in ovarian cancer. J Onabad Med Univ. 2003;16(3):5–20.Google Scholar
- 3.Motevali Zadeh A, Aslani F, Lakpour N. Application of genomics and proteomics technologies for early detection of cancers of the reproductive system. J Fertil Infertil. 2004;10:259–78.Google Scholar
- 4.National Institutes of Health, U.S. Department of Health and Human Services, Last updated October 2011. http://www.cancer.gov/aboutnci/servingpeople/cancer-statistics/snapshots.
- 5.Ghayuori A, Betash N, Fakhr F. Early symptoms of ovarian cancer in young women: a case–control study in oncology ward of Imam Khomeini hospital. J Med Counc Islam Repub Iran. 2003;24(3):250–6.Google Scholar
- 11.Longuespée R, Gagnon H, Boyon C, Strupat K, Dauly C, Kerdraon O, Ighodaro A, Desmons A, Dupuis J, Wisztorski M, Vinatier D, Fournier I, Day R, Salzet M. Proteomic analyses of serous and endometrioid epithelial ovarian cancers—cases studies—molecular insights of a possible histological etiology of serous ovarian cancer. Proteom Clin Appl. 2013;7(5–6):337–54.CrossRefGoogle Scholar
- 13.Felix L, Natasha M, Eleftherios P, Diamandisa, Vathany K. Advances in mass spectrometry-based technologies to direct personalized medicine in ovarian cancer. Transit Proteom. 2013;5(2):76–84. Google Scholar